This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2021 Apr 1;81(7):1922.

doi: 10.1158/0008-5472.CAN-21-0525.

Local Targeting of NAD⁺ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

Ming Li, Ameya R Kirtane, Juri Kiyokawa, Hiroaki Nagashima, Aaron Lopes, Zain A Tirmizi, Christine K Lee, Giovanni Traverso, Daniel P Cahill, Hiroaki Wakimoto

PMID: 34003791
DOI: 10.1158/0008-5472.CAN-21-0525

Published Erratum

Local Targeting of NAD⁺ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

Ming Li et al. Cancer Res. 2021.

. 2021 Apr 1;81(7):1922.

doi: 10.1158/0008-5472.CAN-21-0525.

Authors

Ming Li, Ameya R Kirtane, Juri Kiyokawa, Hiroaki Nagashima, Aaron Lopes, Zain A Tirmizi, Christine K Lee, Giovanni Traverso, Daniel P Cahill, Hiroaki Wakimoto

PMID: 34003791
DOI: 10.1158/0008-5472.CAN-21-0525

No abstract available

PubMed Disclaimer

Erratum for

Local Targeting of NAD⁺ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma.
Li M, Kirtane AR, Kiyokawa J, Nagashima H, Lopes A, Tirmizi ZA, Lee CK, Traverso G, Cahill DP, Wakimoto H. Li M, et al. Cancer Res. 2020 Nov 15;80(22):5024-5034. doi: 10.1158/0008-5472.CAN-20-1094. Epub 2020 Sep 30. Cancer Res. 2020. PMID: 32998997 Free PMC article.

Similar articles

Local Targeting of NAD⁺ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma.
Li M, Kirtane AR, Kiyokawa J, Nagashima H, Lopes A, Tirmizi ZA, Lee CK, Traverso G, Cahill DP, Wakimoto H. Li M, et al. Cancer Res. 2020 Nov 15;80(22):5024-5034. doi: 10.1158/0008-5472.CAN-20-1094. Epub 2020 Sep 30. Cancer Res. 2020. PMID: 32998997 Free PMC article.
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
Hu J, Xiao Q, Dong M, Guo D, Wu X, Wang B. Hu J, et al. Front Immunol. 2020 Nov 27;11:593219. doi: 10.3389/fimmu.2020.593219. eCollection 2020. Front Immunol. 2020. PMID: 33329583 Free PMC article. Review.
The Current Landscape of Immune Checkpoint Blockade in Glioblastoma.
Akintola OO, Reardon DA. Akintola OO, et al. Neurosurg Clin N Am. 2021 Apr;32(2):235-248. doi: 10.1016/j.nec.2020.12.003. Neurosurg Clin N Am. 2021. PMID: 33781505 Review.
Combination immunotherapy strategies for glioblastoma.
Chan HY, Choi J, Jackson C, Lim M. Chan HY, et al. J Neurooncol. 2021 Feb;151(3):375-391. doi: 10.1007/s11060-020-03481-0. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611705 Review.
Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J, Hong J, Lee J, Fakhraei Lahiji S, Kim YH. Kim J, et al. J Control Release. 2021 Apr 10;332:109-126. doi: 10.1016/j.jconrel.2021.02.002. Epub 2021 Feb 8. J Control Release. 2021. PMID: 33571549 Review.

See all similar articles

Cited by

A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1.
Deng Y, Hu B, Miao Y, Wang J, Zhang S, Wan H, Wu Z, Lv Y, Feng J, Ji N, Park D, Hao S. Deng Y, et al. Front Oncol. 2022 Apr 20;12:836257. doi: 10.3389/fonc.2022.836257. eCollection 2022. Front Oncol. 2022. PMID: 35515130 Free PMC article.
T cell exhaustion in malignant gliomas.
Watowich MB, Gilbert MR, Larion M. Watowich MB, et al. Trends Cancer. 2023 Apr;9(4):270-292. doi: 10.1016/j.trecan.2022.12.008. Epub 2023 Jan 19. Trends Cancer. 2023. PMID: 36681605 Free PMC article. Review.

References

1. Li M, Kirtane AR, Kiyokawa J, Nagashima H, Lopes A, Tirmizi ZA, et al. Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma. Cancer Res. 2020;80:5024–34.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations